Eli Lilly Goes All In on Obesity Drugs, Seeking Billions in Revenue
-
Eli Lilly is aggressively pursuing the huge and growing obesity drug market, planning to expand indications for existing drugs like tirzepatide and acquire companies developing new obesity treatments.
-
Eli Lilly believes combining multiple obesity drugs with different mechanisms of action can improve efficacy over single drugs.
-
Eli Lilly aims to offer specialized obesity treatments for diverse comorbidities and capture multiple market niches.
-
Eli Lilly is outpacing competitor Novo Nordisk in expanding its obesity drug portfolio.
-
Eli Lilly's obesity drug strategy could yield billions in revenue and makes it a compelling investment.